Rhythm Pharmaceuticals (RYTM) Net Income towards Common Stockholders (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) reported Net Income towards Common Stockholders of -$56.7 million for Q1 2026, down 11.65% year-over-year from -$64.2 million in Q1 2025, and down 16.19% quarter-over-quarter from -$48.8 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$56.7 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$56.7 million, down 11.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$207.8 million (down 19.46% YoY), and the FY2025 annual result was -$201.9 million, up 23.68% from the prior year.
- Net Income towards Common Stockholders fell to -$56.7 million in Q1 2026 per RYTM's latest filing, from -$48.8 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$33.6 million in Q2 2024 and troughed at -$141.4 million in Q1 2024.
- A 5-year average of -$52.3 million and a median of -$46.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders tumbled 220.07% in 2022, then jumped 64.05% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then slipped by 7.2% to -$44.6 million in 2024, then retreated by 9.42% to -$48.8 million in 2025, then dropped by 16.19% to -$56.7 million in 2026.
- Business Quant data shows RYTM's Net Income towards Common Stockholders at -$56.7 million in Q1 2026, -$48.8 million in Q4 2025, and -$54.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Rhythm Pharmaceuticals | 6.59 Bn | 6.25 Bn | 52.96 Mn | -56.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.74 Mn |
| Dec 31, 2025 | -48.84 Mn |
| Sep 30, 2025 | -54.28 Mn |
| Jun 30, 2025 | -47.98 Mn |
| Mar 31, 2025 | -50.82 Mn |
| Dec 31, 2024 | -44.63 Mn |
| Sep 30, 2024 | -44.97 Mn |
| Jun 30, 2024 | -33.56 Mn |
| Mar 31, 2024 | -141.37 Mn |
| Dec 31, 2023 | -41.63 Mn |
| Sep 30, 2023 | -44.16 Mn |
| Jun 30, 2023 | -46.70 Mn |
| Mar 31, 2023 | -52.18 Mn |
| Dec 31, 2022 | -42.49 Mn |
| Sep 30, 2022 | -40.86 Mn |
| Jun 30, 2022 | -44.87 Mn |
| Mar 31, 2022 | -52.53 Mn |
| Dec 31, 2021 | -50.86 Mn |
| Sep 30, 2021 | -35.11 Mn |
| Jun 30, 2021 | -35.39 Mn |